未登录

C

Cheng-Bo Han

Department of Oncology

H指数:20

被引数:1,229

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative Efficacy of First-Line Therapies for PD-L1-Negative Advanced NSCLC: A Network Meta-Analysis with Reconstructed Survival Curves

PD-L1阴性晚期非小细胞肺癌一线疗法比较疗效：一项基于重构生存曲线的网络Meta分析

critical reviews in oncology hematology

IF0

2025-07-150

PRE

Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung Cancer

免疫治疗增强的立体定向消融放射治疗在不可手术的早期非小细胞肺癌中的应用

CURRENT TREATMENT OPTIONS IN ONCOLOGY

IF4.7

2025-05-080

PRE

Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study

JTO CLINICAL AND RESEARCH REPORTS

IF3.5

2025-02-010

OA

Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells

MOLECULAR CANCER

IF33.9

2024-11-190

OAAI

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2024-10-171

OAAI

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

SCIENTIFIC REPORTS

IF3.9

2024-10-020

OAAI

Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial

NATURE COMMUNICATIONS

IF15.7

2024-08-220

OAAI

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2024-08-050

OAAI

Zhong, Qiaofeng; Zhang, Longfeng; Wu, Lin; Zhao, Jun; Sun, Jianguo; Fang, Yong; Zhou, Jin; Chu, Qian; Shen, Yihong; Yang, Zhenzhou; Chen, Lijin; Huang, Meijuan; Lin, Xiaoyan; Liu, Zhenhua; Shen, Peng; Wang, Zhijie; Wang, Xin; Wang, Huijuan; Han, Chengbo; Liu, Anwen; Zhang, Hongmei; Ye, Feng; Gao, Wen; Wu, Fang; Song, Zhengbo; Chen, Shengchi; Zhou, Chengzhi; Huang, Dingzhi; Zhang, Qiuyu; Zheng, Xinlong; Zheng, Xiaobin; Miao, Qian; Jiang, Kan; Zou, Zihua; Xu, Yiquan; Wu, Shiwen; Wang, Haibo; Hong, Yaping; Lu, Tao; Li, Chao; Huang, Cheng; Chen, Chuanben; Lin, Gen

Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2024-05-010

PRE

Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)

ANNALS OF ONCOLOGY

IF65.4

2023-11-011

PRE

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

IF3.4

2023-08-012

OAAI

Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2023-07-015

OAAI

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-077

OAAI

Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-03-319

OAAI

Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

RADIATION ONCOLOGY

IF3.2

2021-09-1518

OAAI

Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

IF3.4

2021-04-178

OAAI

Short-term outcomes and safety of radiotherapy for immediate breast reconstruction with autologous flap transfer following breast-conserving surgery

保乳术后自体皮瓣移植即刻乳房重建放疗的近期疗效和安全性

IF3.4

2021-03-024

OAAI

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

FRONTIERS IN ONCOLOGY

IF3.3

2021-01-1253

OAAI

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

FRONTIERS IN ONCOLOGY

IF3.3

2020-12-1071

OAAI

Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

RADIATION ONCOLOGY

IF3.2

2020-08-2413

OAAI